Guilford (GLFD) - Steadily Rising Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Guilford (GLFD) - Steadily Rising

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Dan Peer who wrote (24)	3/18/1997 9:14:00 PM
From: SteveG	of 496

Dan- Just checked in here, but didn't see an accurate response. The most obvious cause of this pullback, as you probably already know by now, is the planned offering of 3.25M dilutive secondary shares. If the green shoe is filled, this will be dilutive by almost 21%. Alex brown's analyst Kevin Tang (one of the best biotech analysts around IMO, and GLFD is his #1 pick) has not yet readjusted his 12 month price target of $38 on the basis of the anticipated diluted EPS yet. I think GLFD is a compelling company for the future, especially with their neuroprotective/neuroregenerative oral treatment (neuroimmunophillin - GPI-1046). It's potential with Parkinsons and Alzheimers patients is significant to watch for clinical results from. My guess is that the stock is priced at a discount (to market close) on the offering, and may "langer" (think linger + languish) for awhile before interest in resurges. -Steve

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next